- Research Article
- 10.54254/2753-7048/2026.zju31872
Conventional and mRNA Vaccine Treatments for Pancreatic Cancer
- Feb 24, 2026
- Lecture Notes in Education Psychology and Public Media
- Yue Zhang
Pancreatic cancer is a highly invasive tumor that has an extremely low probability of prediction. The impact of traditional treatment procedures such as surgery, chemotherapy and radiotherapy is still insufficient and new treatment approaches is in urgent need. Cancer immunotherapy particularly vaccine treatment has taken centre stage in research in the recent years. This is a review of research advances with both conventional vaccines and up-and-coming mRNA vaccines used in the treatment of pancreatic cancer therapy. Conventional vaccines consist of dendritic cell vaccines, exosome vaccines and peptide vaccinations, etc. Such vaccines have anti-tumor effects inducing antigen presentation and T-cell responses and were found to have some safety and immune activity in clinical trials. Nevertheless, these methods continue to have issues including the lack of immunogenicity, low level of personalization, complicated processes of preparation and suppression of tumor microenvironment. By comparison, mRNA vaccines, featuring the benefits of an extremely personalized vaccine design, can be well engineered in a short time and very immunogenic, have the potential to encode patient-specific neoantigens and induce long-lasting T-cell responses, which are one potential means of overcoming the cold tumor phenotype of pancreatic cancer. The paper provides a systematic discussion of classification and mechanisms of traditional vaccines and the research progress and perspective of mRNA vaccines, outlines characteristics of action, existent limitations and future directions of development of a variety of vaccines, attempting to provide references to further studies and clinical application of pancreatic cancer immunotherapy.
Read more